Status:
COMPLETED
A Study of RO4917523 in Patients With Treatment Resistant Depression
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison to placebo, in patients with treatment-resistant depression. Following a washout period from existing anti-de...
Eligibility Criteria
Inclusion
- adult patients, 18-65 years of age;
- recurrent major depressive disorder, without psychotic features;
- at least 3 lifetime treatment failures, at least 2 of which must have occurred within the current depressive episode;
- baseline minimal severity defined by a HAM-D score of 18 or above;
- willing to be hospitalized for at least 16 consecutive days.
Exclusion
- history of bipolar disorder, schizoaffective disorder or schizophrenia;
- history of psychosis, including psychotic depression;
- significant past or present neurological disorder, including seizures, stroke and/or head trauma.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00809562
Start Date
March 1 2009
End Date
February 1 2011
Last Update
November 2 2016
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Oceanside, California, United States, 92056
2
San Diego, California, United States, 92103
3
New Haven, Connecticut, United States, 06511
4
Shreveport, Louisiana, United States, 71115